GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Repare Therapeutics Inc (NAS:RPTX) » Definitions » Cash per Share

Repare Therapeutics (Repare Therapeutics) Cash per Share : $5.58 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Repare Therapeutics Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Repare Therapeutics's Cash per Share for the quarter that ended in Mar. 2024 was $5.58.


Repare Therapeutics Cash per Share Historical Data

The historical data trend for Repare Therapeutics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repare Therapeutics Cash per Share Chart

Repare Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash per Share
Get a 7-Day Free Trial 3.01 9.04 8.17 8.18 5.30

Repare Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.47 6.67 5.94 5.30 5.58

Repare Therapeutics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Repare Therapeutics's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Repare Therapeutics's Cash per Share for the quarter that ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Repare Therapeutics  (NAS:RPTX) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.


Repare Therapeutics Cash per Share Related Terms

Thank you for viewing the detailed overview of Repare Therapeutics's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Repare Therapeutics (Repare Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
7210 Frederick-Banting Street, Suite 100, Saint-Laurent, QC, CAN, H4S 2A1
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
Executives
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Michael Zinda officer: EVP, Chief Science Officer C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100, ST-LAURENT A8 H4S 2A1
Susan Molineaux director C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080
Davis Jerel director, 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures V, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage I, L.p. 10 percent owner ONE SANSOME, SUITE 1650, SAN FRANCISCO CA 94104
Thomas Civik director C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104

Repare Therapeutics (Repare Therapeutics) Headlines

From GuruFocus

Repare Therapeutics to Participate in Two Upcoming Investor Conferences

By Business Wire Business Wire 02-02-2023